10-Q 1 mo-20240331.htm 10-Q mo-20240331
false2024Q1000076418012/310.33330.3333http://fasb.org/us-gaap/2023#AccountsPayableCurrent14300007641802024-01-012024-03-310000764180mo:CommonStock0.3313ParValueMember2024-01-012024-03-310000764180mo:CommonStock1.700NotesDue2025Member2024-01-012024-03-310000764180mo:CommonStock2.200NotesDue2027Member2024-01-012024-03-310000764180mo:CommonStock3.125NotesDue2031Member2024-01-012024-03-3100007641802024-04-16xbrli:shares00007641802024-03-31iso4217:USD00007641802023-12-31iso4217:USDxbrli:shares00007641802023-01-012023-03-310000764180us-gaap:CommonStockMember2023-12-310000764180us-gaap:AdditionalPaidInCapitalMember2023-12-310000764180us-gaap:RetainedEarningsMember2023-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000764180us-gaap:TreasuryStockCommonMember2023-12-310000764180us-gaap:NoncontrollingInterestMember2023-12-310000764180us-gaap:RetainedEarningsMember2024-01-012024-03-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000764180us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000764180us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000764180us-gaap:CommonStockMember2024-03-310000764180us-gaap:AdditionalPaidInCapitalMember2024-03-310000764180us-gaap:RetainedEarningsMember2024-03-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000764180us-gaap:TreasuryStockCommonMember2024-03-310000764180us-gaap:NoncontrollingInterestMember2024-03-310000764180us-gaap:CommonStockMember2022-12-310000764180us-gaap:AdditionalPaidInCapitalMember2022-12-310000764180us-gaap:RetainedEarningsMember2022-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000764180us-gaap:TreasuryStockCommonMember2022-12-310000764180us-gaap:NoncontrollingInterestMember2022-12-3100007641802022-12-310000764180us-gaap:RetainedEarningsMember2023-01-012023-03-310000764180us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000764180us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000764180us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000764180us-gaap:CommonStockMember2023-03-310000764180us-gaap:AdditionalPaidInCapitalMember2023-03-310000764180us-gaap:RetainedEarningsMember2023-03-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000764180us-gaap:TreasuryStockCommonMember2023-03-310000764180us-gaap:NoncontrollingInterestMember2023-03-3100007641802023-03-310000764180us-gaap:AdditionalPaidInCapitalMembermo:January2024AcceleratedShareRepurchaseProgramMember2024-03-31xbrli:pure0000764180us-gaap:AdditionalPaidInCapitalMembermo:ASRAgreementsMember2024-01-012024-03-310000764180us-gaap:AdditionalPaidInCapitalMembermo:ASRAgreementsMember2024-03-310000764180mo:PhilipMorrisUSAMembermo:HorizonMember2024-03-310000764180mo:HorizonMembermo:JTIUHMember2024-03-310000764180mo:January2023ShareRepurchaseProgramMember2023-01-310000764180mo:January2024ShareRepurchaseProgramMember2024-01-310000764180mo:January2024ShareRepurchaseProgramMember2024-03-310000764180mo:ASRAgreementsMember2024-03-310000764180mo:ASRAgreementsMember2024-03-012024-03-310000764180mo:ASRAgreementsMember2024-01-012024-03-310000764180srt:ScenarioForecastMembermo:ASRAgreementsMember2024-06-300000764180srt:ScenarioForecastMembermo:ASRAgreementsMember2024-04-012024-06-300000764180mo:January2023ShareRepurchaseProgramMember2023-01-012023-03-310000764180mo:NJOYHoldingsIncMember2023-06-012023-06-010000764180mo:NJOYHoldingsIncMember2023-06-010000764180mo:NJOYHoldingsIncMember2024-03-310000764180mo:NJOYHoldingsIncMember2023-12-310000764180mo:NJOYHoldingsIncMemberus-gaap:DevelopedTechnologyRightsMember2023-06-010000764180mo:NJOYHoldingsIncMemberus-gaap:DevelopedTechnologyRightsMember2024-03-310000764180mo:NJOYHoldingsIncMemberus-gaap:TrademarksMember2023-06-010000764180mo:NJOYHoldingsIncMemberus-gaap:TrademarksMember2024-01-012024-03-310000764180mo:NJOYHoldingsIncMemberus-gaap:TrademarksMember2024-03-310000764180mo:NJOYHoldingsIncMembermo:SupplierAgreementsMember2023-06-010000764180mo:NJOYHoldingsIncMembermo:SupplierAgreementsMember2024-01-012024-03-310000764180mo:NJOYHoldingsIncMembermo:SupplierAgreementsMember2024-03-310000764180mo:NJOYHoldingsIncMember2024-01-012024-03-310000764180mo:NJOYHoldingsIncMember2024-03-312024-03-3100007641802023-06-010000764180mo:NJOYHoldingsIncMembersrt:WeightedAverageMember2023-06-012023-06-010000764180mo:ABInBevMember2024-03-310000764180mo:ABInBevMember2023-12-310000764180mo:CronosGroupInc.Member2024-03-310000764180mo:CronosGroupInc.Member2023-12-310000764180mo:ABInBevMember2024-01-012024-03-310000764180mo:ABInBevMember2023-01-012023-03-310000764180mo:CronosGroupInc.Member2024-01-012024-03-310000764180mo:CronosGroupInc.Member2023-01-012023-03-310000764180mo:JUULMember2024-01-012024-03-310000764180mo:JUULMember2023-01-012023-03-310000764180mo:ABInBevMember2024-03-1300007641802024-03-142024-03-140000764180mo:ABInBevMembermo:SecondaryOfferingMember2024-03-192024-03-190000764180mo:ABInBevMembermo:SecondaryOfferingMember2024-03-190000764180mo:ABInBevMemberus-gaap:OverAllotmentOptionMember2024-03-192024-03-190000764180mo:ABInBevMemberus-gaap:PrivatePlacementMember2024-03-192024-03-190000764180mo:ABInBevMembermo:MarketingAdministrationAndResearchCostsMember2024-01-012024-03-310000764180mo:ABInBevMembermo:InterestIncomeExpenseNetMember2024-01-012024-03-31mo:board_member0000764180us-gaap:FairValueInputsLevel1Membermo:ABInBevMember2024-03-310000764180us-gaap:FairValueInputsLevel1Membermo:ABInBevMember2023-12-31mo:contract0000764180mo:ForeignCurrencyDenominatedDebtMember2024-03-310000764180mo:ForeignCurrencyDenominatedDebtMember2023-12-310000764180mo:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-03-310000764180mo:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-03-310000764180us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000764180us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-03-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-03-310000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-03-310000764180srt:MaximumMemberus-gaap:PensionPlansDefinedBenefitMember2024-03-310000764180srt:MaximumMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-03-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2023-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2024-01-012024-03-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2024-03-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2022-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2023-01-012023-03-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2023-03-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-01-012024-03-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-01-012023-03-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMembermo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2024-01-012024-03-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMembermo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2023-01-012023-03-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000764180mo:SmokeableProductsSegmentMember2024-01-012024-03-310000764180mo:SmokeableProductsSegmentMember2023-01-012023-03-310000764180mo:OralTobaccoSegmentMember2024-01-012024-03-310000764180mo:OralTobaccoSegmentMember2023-01-012023-03-310000764180us-gaap:AllOtherSegmentsMember2024-01-012024-03-310000764180us-gaap:AllOtherSegmentsMember2023-01-012023-03-310000764180mo:SmokeableProductsSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000764180mo:SmokeableProductsSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000764180mo:OralTobaccoSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000764180mo:OralTobaccoSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000764180us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000764180us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000764180us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000764180us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000764180mo:SmokeableProductsSegmentMembermo:PhilipMorrisUSAMembermo:MarketingAdministrationAndResearchCostsMemberus-gaap:OperatingSegmentsMembermo:TobaccoandHealthLitigationCasesMember2024-01-012024-03-310000764180mo:SmokeableProductsSegmentMembermo:PhilipMorrisUSAMembermo:MarketingAdministrationAndResearchCostsMemberus-gaap:OperatingSegmentsMembermo:TobaccoandHealthLitigationCasesMember2023-01-012023-03-310000764180us-gaap:CorporateNonSegmentMembermo:TobaccoandHealthLitigationCasesMember2024-01-012024-03-310000764180us-gaap:CorporateNonSegmentMembermo:TobaccoandHealthLitigationCasesMember2023-01-012023-03-310000764180us-gaap:MaterialReconcilingItemsMembermo:InterestAndOtherDebtExpenseNetMembermo:TobaccoandHealthLitigationCasesMember2024-01-012024-03-310000764180us-gaap:MaterialReconcilingItemsMembermo:InterestAndOtherDebtExpenseNetMembermo:TobaccoandHealthLitigationCasesMember2023-01-012023-03-310000764180mo:TobaccoandHealthLitigationCasesMember2024-01-012024-03-310000764180mo:TobaccoandHealthLitigationCasesMember2023-01-012023-03-310000764180mo:RevolvingCreditFacilityDueOctober242028Memberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2024-03-31mo:period0000764180mo:RevolvingCreditFacilityDueOctober242028Memberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000764180mo:RevolvingCreditFacilityDueOctober242028Membermo:TermSecuredOvernightFinancingRateTermSOFRMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000764180us-gaap:SeniorNotesMembermo:USDNotes4000MaturingJanuary2024Member2024-01-310000764180mo:USDNotes3.800MaturingFeburary2024Memberus-gaap:SeniorNotesMember2024-02-280000764180us-gaap:SeniorNotesMembermo:USDNotes4000MaturingJanuary2024Member2024-01-012024-01-310000764180mo:USDNotes3.800MaturingFeburary2024Memberus-gaap:SeniorNotesMember2024-02-012024-02-28mo:state0000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2024-01-012024-03-310000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2023-01-012023-03-310000764180mo:AgreementToResolveShareholderClassActionMembermo:LitigationCasesResultsMember2024-01-012024-03-310000764180mo:AgreementToResolveShareholderClassActionMembermo:LitigationCasesResultsMember2023-01-012023-03-310000764180mo:JUULMembermo:LitigationCasesResultsMember2024-01-012024-03-310000764180mo:JUULMembermo:LitigationCasesResultsMember2023-01-012023-03-310000764180mo:InterestExpenseRelatedToLitigationMember2024-01-012024-03-310000764180mo:InterestExpenseRelatedToLitigationMember2023-01-012023-03-310000764180mo:TobaccoandHealthJudgmentMember2004-10-012024-03-310000764180mo:EngleProgenyCasesMember2004-10-012024-03-310000764180mo:PhilipMorrisUSAMemberus-gaap:AssetsMemberus-gaap:PendingLitigationMember2024-03-310000764180us-gaap:SubsequentEventMembermo:IndividualSmokingAndHealthCasesMember2024-04-22mo:claim0000764180mo:IndividualSmokingAndHealthCasesMember2023-04-240000764180mo:IndividualSmokingAndHealthCasesMember2022-04-250000764180mo:HealthCareCostRecoveryActionsMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:HealthCareCostRecoveryActionsMember2023-04-240000764180mo:HealthCareCostRecoveryActionsMember2022-04-250000764180mo:EvaporLitigationMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:EvaporLitigationMember2023-04-240000764180mo:EvaporLitigationMember2022-04-250000764180mo:OtherTabaccoRelatedCasesMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:OtherTabaccoRelatedCasesMember2023-04-240000764180mo:OtherTabaccoRelatedCasesMember2022-04-250000764180us-gaap:SubsequentEventMembermo:IndividualSmokingAndHealthCasesMemberus-gaap:PendingLitigationMemberstpr:IL2024-04-220000764180us-gaap:SubsequentEventMemberstpr:NMmo:IndividualSmokingAndHealthCasesMemberus-gaap:PendingLitigationMember2024-04-220000764180stpr:MAus-gaap:SubsequentEventMembermo:IndividualSmokingAndHealthCasesMemberus-gaap:PendingLitigationMember2024-04-220000764180us-gaap:SubsequentEventMemberstpr:FLmo:IndividualSmokingAndHealthCasesMemberus-gaap:PendingLitigationMember2024-04-220000764180us-gaap:SubsequentEventMembermo:ETSSmokingandHealthCaseFlightAttendantsMemberus-gaap:PendingLitigationMember2024-04-222024-04-22mo:casemo:lawsuit0000764180mo:EvaporLitigationMembermo:PendingIndividualLawsuitsMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:PendingLawsuitsFiledByStateOrLocalGovernmentsMembermo:EvaporLitigationMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:ClassActionLawsuitMembermo:EvaporLitigationMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:EvaporLitigationMember2023-05-310000764180mo:EvaporLitigationMemberus-gaap:SubsequentEventMembercountry:CA2024-04-220000764180mo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembercountry:CA2024-04-220000764180mo:PhilipMorrisUSAandAltriaGroupMembermo:HealthCareCostRecoveryActionsMemberus-gaap:SubsequentEventMembercountry:CA2024-04-220000764180mo:PhilipMorrisUSAandAltriaGroupMemberus-gaap:SubsequentEventMembermo:SmokingAndHealthClassActionsMembercountry:CA2024-04-220000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:IndividualSmokingAndHealthCasesMember2024-04-220000764180mo:PhilipMorrisUSAMembermo:EvaporLitigationMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012024-04-220000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseTaylorMemberus-gaap:SubsequentEventMember2024-04-250000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseRoachMember2023-12-310000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseRicaporHallMember2023-08-310000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseRicaporHallMember2023-10-012023-10-310000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseRicaporHallMember2023-10-310000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseDeswertMember2023-05-310000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseWoodleyMember2023-02-280000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseFontaineMember2022-09-300000764180mo:NonEngleProgenySmokingAndHealthCaseFontaineMember2023-09-300000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingAndHealthCaseFontaineMember2023-12-310000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingandHealthCaseGreeneMember2019-09-300000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingandHealthCaseGreeneMember2020-05-310000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingandHealthCaseGreeneMember2021-02-280000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingandHealthCaseGreeneMember2023-04-012023-06-300000764180mo:EngleProgenyCasesMember2008-01-310000764180mo:EngleProgenyCasesStateMemberus-gaap:SubsequentEventMember2024-04-220000764180mo:EngleProgenyCasesStateMemberus-gaap:SubsequentEventMember2024-04-222024-04-22mo:plantiff0000764180mo:EngleProgenyCasesMemberus-gaap:SubsequentEventMember2024-04-222024-04-220000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMemberus-gaap:SubsequentEventMember2024-04-222024-04-220000764180mo:EngleProgenyCasesChaconMemberus-gaap:PendingLitigationMember2023-10-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesChaconMemberus-gaap:PendingLitigationMember2023-10-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesHoffmanMember2023-01-310000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesHoffmanMember2023-01-310000764180mo:EngleProgenyCasesLevineMemberus-gaap:PendingLitigationMember2022-09-300000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesLevineMemberus-gaap:PendingLitigationMember2022-09-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesSchertzerMember2022-04-300000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesSchertzerMember2022-04-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesLippMember2021-09-300000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesLippMember2021-09-300000764180mo:EngleProgenyCasesMcCallMemberus-gaap:PendingLitigationMember2019-03-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMcCallMemberus-gaap:PendingLitigationMember2019-03-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesChadwellMember2018-09-300000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesChadwellMemberus-gaap:PendingLitigationMember2018-09-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesKaplanMcLauighlinMember2018-07-310000764180mo:PhilipMorrisUSAMemberus-gaap:PendingLitigationMembermo:EngleProgenyCasesKaplanMcLauighlinMember2018-07-310000764180mo:EngleProgenyCasesCooperMemberus-gaap:PendingLitigationMember2015-09-300000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesCooperMemberus-gaap:PendingLitigationMember2015-09-300000764180mo:EngleProgenyCasesDuignanMemberus-gaap:SettledLitigationMember2023-04-012024-03-310000764180us-gaap:SettledLitigationMembermo:EngleProgenyCasesFerraiuoloMember2023-04-012024-03-310000764180mo:EngleProgenyCasesGarciaMemberus-gaap:SettledLitigationMember2023-04-012024-03-310000764180mo:EngleProgenyCasesHollimanMemberus-gaap:SettledLitigationMember2023-04-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:AR1996-05-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:CAmo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180stpr:DEmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:DCmo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:FL1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:IL1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:IA1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:KS1996-05-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:LAmo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:MD1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:MI1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:MN1996-05-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:NVmo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:NJ1996-05-012024-03-310000764180stpr:NYmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:OHmo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:OKmo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:OR1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:PA1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembercountry:PRmo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:SCmo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:TX1996-05-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:WImo:SmokingAndHealthClassActionsMember1996-05-012024-03-310000764180mo:PhilipMorrisUSAandAltriaGroupMembermo:BritishColumbiaSaskatchewanMemberus-gaap:SubsequentEventMembermo:SmokingAndHealthClassActionsMember2024-04-220000764180mo:CanadianTobaccoManufacturersMembermo:SmokingAndHealthClassActionsMembercountry:CA2019-03-31mo:manufacture0000764180mo:AltriaGroupMembermo:SmokingAndHealthClassActionsMembercountry:CA2019-03-31mo:ruling0000764180mo:CanadianTobaccoManufacturersMembermo:SmokingAndHealthClassActionsMembercountry:CA2019-03-012019-03-31iso4217:CAD0000764180mo:HealthCareCostRecoveryActionsMemberus-gaap:ThreatenedLitigationMembercountry:CA2024-03-310000764180mo:CanadianTobaccoManufacturersMembermo:SmokingAndHealthClassActionsMembercountry:CA2024-03-310000764180mo:HealthCareCostRecoveryActionsMember1998-11-011998-11-300000764180mo:HealthCareCostRecoveryActionsMember1998-11-300000764180mo:HealthCareCostRecoveryActionsMember2024-01-012024-03-310000764180mo:HealthCareCostRecoveryActionsMember2023-01-012023-03-310000764180mo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMemberus-gaap:SettledLitigationMember2022-01-012022-01-310000764180mo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMember1998-01-012024-03-310000764180mo:PhilipMorrisUSAMemberstpr:IL2022-01-012022-03-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsTransitionYears20192021Memberus-gaap:SettledLitigationMemberstpr:IL2022-01-012022-03-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsTransitionYears20052022Memberus-gaap:PendingLitigationMemberstpr:IA2023-08-012023-08-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsTransitionYears20202022Memberus-gaap:PendingLitigationMemberstpr:IA2023-08-012023-08-310000764180mo:PhilipMorrisUSAMemberstpr:IA2023-07-012023-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsTransitionYears20052022Memberstpr:IDus-gaap:PendingLitigationMember2024-02-012024-02-280000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActionsTransitionYears20212023Memberstpr:IDus-gaap:PendingLitigationMember2024-02-012024-02-280000764180mo:PhilipMorrisUSAMemberstpr:ID2024-01-012024-03-310000764180mo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMember2014-01-012024-03-310000764180mo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMember2024-01-012024-03-310000764180stpr:NYmo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMemberus-gaap:SettledLitigationMember2015-01-012015-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMemberus-gaap:PendingLitigationMember2024-01-012024-03-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMemberus-gaap:PendingLitigationMember2023-04-012023-04-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMemberus-gaap:PendingLitigationMember2021-07-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMemberus-gaap:PendingLitigationMember2022-10-012022-12-310000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20052007NPMAdjustmentMemberus-gaap:PendingLitigationMember2024-01-012024-03-310000764180mo:PhilipMorrisUSAMembermo:PeriodOneMembermo:HealthCareCostRecoveryActions20052007NPMAdjustmentMemberus-gaap:PendingLitigationMember2024-01-012024-03-310000764180mo:PeriodTwoMembermo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20052007NPMAdjustmentMemberus-gaap:PendingLitigationMember2024-01-012024-03-310000764180mo:PhilipMorrisUSAMembermo:PeriodOneMembermo:HealthCareCostRecoveryActions20052007NPMAdjustmentMemberus-gaap:SubsequentEventMemberus-gaap:PendingLitigationMember2024-04-222024-04-220000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20052007NPMAdjustmentMemberus-gaap:PendingLitigationMember2023-10-012023-12-310000764180mo:OtherDisputesUndertheStateSettlementAgreementsMembermo:PhilipMorrisUSAMember2021-01-012021-01-310000764180mo:FederalGovernmentsLawsuitMember2017-10-012017-12-310000764180mo:FederalGovernmentsLawsuitMember2018-10-012018-12-310000764180mo:FederalGovernmentsLawsuitMembermo:ImplementationofCorrectiveCommunicationsMember2022-01-012022-12-310000764180mo:FederalGovernmentsLawsuitMembermo:ImplementationofCorrectiveCommunicationsMember2024-01-012024-03-310000764180mo:PendingClassActionLawsuitMembermo:EvaporLitigationMemberus-gaap:SubsequentEventMembercountry:CA2024-04-220000764180mo:EvaporLitigationMember2023-05-012023-05-31mo:thirdPartyClaim0000764180mo:EvaporLitigationMember2023-08-012023-08-310000764180mo:EvaporLitigationMember2023-07-012023-09-300000764180mo:EvaporLitigationMember2023-06-012023-06-300000764180mo:IQOSMember2022-09-012022-09-300000764180mo:IQOSMember2023-01-310000764180mo:IQOSMember2020-04-012020-04-300000764180mo:JUULMember2020-04-300000764180us-gaap:SubsequentEventMember2024-04-2200007641802020-11-30mo:complaint00007641802022-03-012022-03-3100007641802021-01-012021-12-3100007641802022-01-012022-01-310000764180mo:FederalAndStateShareholderDerivativeLawsuitsMember2023-05-012023-05-310000764180mo:FederalAndStateShareholderDerivativeLawsuitsMember2022-01-012022-12-310000764180mo:FederalAndStateShareholderDerivativeLawsuitsMember2023-03-310000764180mo:FederalAndStateShareholderDerivativeLawsuitsMember2023-04-012023-04-300000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:LightsMember2024-04-22mo:court0000764180us-gaap:SubsequentEventMembermo:LightsMember2024-04-220000764180us-gaap:SubsequentEventMembermo:SmokingAndHealthClassActionsMember2024-04-220000764180mo:USTLitigationMembermo:PendingIndividualLawsuitsMemberus-gaap:SubsequentEventMember2024-04-220000764180us-gaap:LetterOfCreditMember2024-03-310000764180mo:RevolvingCreditFacilityDueOctober242028Membermo:CreditAgreementMember2024-03-310000764180mo:ImplementationofCorrectiveCommunicationsMember2018-10-012018-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                    
Commission File Number 1-08940
Altria Group, Inc.
(Exact name of registrant as specified in its charter)
Virginia 13-3260245
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer
Identification No.)
6601 West Broad Street,Richmond,Virginia23230
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (804) 274-2200 
 Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
               Title of each class               
Trading SymbolsName of each exchange on which registered
Common Stock, $0.33 1/3 par value
MONew York Stock Exchange
1.700% Notes due 2025
MO25New York Stock Exchange
2.200% Notes due 2027
MO27New York Stock Exchange
3.125% Notes due 2031
MO31New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes   þ     No   ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes   þ    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer þAccelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes    No   þ
At April 16, 2024, there were 1,717,626,424 shares outstanding of the registrant’s common stock, par value $0.33 1/3 per share.




ALTRIA GROUP, INC.
TABLE OF CONTENTS
 
  Page No.
PART I -FINANCIAL INFORMATION
Item 1.Financial Statements (Unaudited)
Item 2.
Item 3.
Item 4.
PART II -OTHER INFORMATION
Item 1.
Item 1A.
Item 2.
Item 5.
Item 6.
Signature

2

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions of dollars)
(Unaudited)
______________________________
 
March 31, 2024December 31, 2023
Assets
Cash and cash equivalents$3,608 $3,686 
Receivables77 71 
Inventories:
Leaf tobacco610 649 
Other raw materials199 204 
Work in process27 22 
Finished product405 340 
1,241 1,215 
Income taxes173 496 
Other current assets99 117 
Total current assets5,198 5,585 
Property, plant and equipment, at cost4,515 4,582 
Less accumulated depreciation2,891 2,930 
1,624 1,652 
Goodwill6,945 6,791 
Other intangible assets, net13,439 13,686 
Investments in equity securities8,396 10,011 
Other assets873 845 
Total Assets$36,475 $38,570 
 
See notes to condensed consolidated financial statements.
3

Altria Group, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Continued)
(in millions of dollars, except share and per share data)
(Unaudited)
________________________________________________
 
March 31, 2024December 31, 2023
Liabilities
Current portion of long-term debt$ $1,121 
Accounts payable504 582 
Accrued liabilities:
Marketing720 716 
Settlement charges3,420 2,563 
Other1,901 1,902 
Deferred gain from the sale of IQOS System commercialization rights
2,700 2,700 
Dividends payable1,690 1,735 
Total current liabilities10,935 11,319 
Long-term debt25,042 25,112 
Deferred income taxes2,699 2,799 
Accrued pension costs128 130 
Accrued postretirement health care costs1,079 1,079 
Other liabilities1,656 1,621 
Total liabilities41,539 42,060 
Contingencies (Note 13)
Stockholders’ Equity (Deficit)
Common stock, par value $0.33 1/3 per share
(2,805,961,317 shares issued)
935 935 
Additional paid-in capital5,521 5,906 
Earnings reinvested in the business31,535 31,094 
Accumulated other comprehensive losses(2,266)(2,673)
Cost of repurchased stock
(1,088,334,893 shares at March 31, 2024 and
1,042,499,542 shares at December 31, 2023)
(40,839)(38,802)
Total stockholders’ equity (deficit) attributable to Altria(5,114)(3,540)
Noncontrolling interests50 50 
Total stockholders’ equity (deficit)(5,064)(3,490)
Total Liabilities and Stockholders’ Equity (Deficit)$36,475 $38,570 

See notes to condensed consolidated financial statements.

4

Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
_____________________________________ 
For the Three Months Ended March 31,20242023
Net revenues$5,576 $5,719 
Cost of sales1,437 1,434 
Excise taxes on products859 956 
Gross profit3,280 3,329 
Marketing, administration and research costs606 572 
Operating income2,674 2,757 
Interest and other debt expense, net254 229 
Net periodic benefit income, excluding service cost(24)(31)
(Income) losses from investments in equity securities(295)80 
Earnings before income taxes2,739 2,479 
Provision for income taxes610 692 
Net earnings$2,129 $1,787 
Per share data:
Basic and diluted earnings per share$1.21 $1.00 

See notes to condensed consolidated financial statements.

5

Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)
_____________________
For the Three Months Ended March 31,20242023
Net earnings$2,129 $1,787 
Other comprehensive earnings (losses), net of deferred income taxes:
Benefit plans(1)(6)
ABI402 (12)
Currency translation adjustments and other6 10 
Other comprehensive earnings (losses), net of deferred income taxes407 (8)
Comprehensive earnings$2,536 $1,779 

See notes to condensed consolidated financial statements.
6

Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
for the Three Months Ended March 31, 2024 and 2023
(in millions of dollars, except per share data)
(Unaudited)
_______________________________________

 Attributable to Altria  
 Common
Stock
Additional
Paid-in
Capital
Earnings
Reinvested
in the
Business
Accumulated
Other
Comprehensive
Losses
Cost of
Repurchased
Stock
Non-
controlling
Interests
Total
Stockholders’
Equity (Deficit)
Balances, December 31, 2023
$935 $5,906 $31,094 $(2,673)$(38,802)$50 $(3,490)
Net earnings  2,129    2,129 
Other comprehensive earnings (losses), net of deferred income taxes   407   407 
Stock award activity (25)  23  (2)
Cash dividends declared ($0.98 per share)
  (1,688)   (1,688)
Repurchases of common stock (360)(1)  (2,040) (2,400)
Other    (20) (20)
Balances, March 31, 2024
$935 $5,521 $31,535 $(2,266)$(40,839)$50 $(5,064)
Balances, December 31, 2022
$935 $5,887 $29,792 $(2,771)$(37,816)$50 $(3,923)
Net earnings— — 1,787 — —  1,787 
Other comprehensive earnings (losses), net of deferred income taxes
— — — (8)— — (8)
Stock award activity
— (21)— — 20 — (1)
Cash dividends declared ($0.94 per share)
— — (1,681)— — — (1,681)
Balances, March 31, 2023
$935 $5,866 $29,898 $(2,779)$(37,796)$50 $(3,826)
(1) Represents the remaining 15% of the Repurchase Price related to the ASR transactions. See Note 1. Background and Basis of Presentation.

See notes to condensed consolidated financial statements.

7

Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions of dollars)
(Unaudited)
_____________________
For the Three Months Ended March 31,20242023
Cash Provided by (Used in) Operating Activities
Net earnings$2,129 $1,787 
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization65 52 
Deferred income tax provision (benefit)(138)(20)
Unrecognized tax benefit (1)
33 269 
(Income) losses from investments in equity securities(295)80 
Cash effects of changes:
Receivables(6)(34)
Inventories(26)(72)
Accounts payable(61)(115)
Income taxes671 409 
Accrued liabilities and other current assets(377)(369)
Accrued settlement charges857 895 
Pension plan contributions(4)(7)
Pension and postretirement, net(29)(34)
Other, net58 143 
Net cash provided by (used in) operating activities2,877 2,984 
Cash Provided by (Used in) Investing Activities
Capital expenditures(35)(55)
Proceeds from the ABI Transaction (2)
2,353  
Other, net(2)(1)
Net cash provided by (used in) investing activities$2,316 $(56)
(1) 2023 relates to unrecognized tax benefit from the ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL, partially offset by our estimated corporate alternative minimum tax credit carryforward.
(2) For further discussion of the ABI Transaction, see Note 5. Investments in Equity Securities.

See notes to condensed consolidated financial statements.
8

Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in millions of dollars)
(Unaudited)
_____________________
For the Three Months Ended March 31,20242023
Cash Provided by (Used in) Financing Activities
Long-term debt repaid$(1,121)$(1,348)
Repurchases of common stock (1)
(2,400) 
Dividends paid on common stock(1,733)(1,683)
Other, net(14)(14)
Net cash provided by (used in) financing activities(5,268)(3,045)
Cash, cash equivalents and restricted cash:
Increase (decrease)(75)(117)
Balance at beginning of period3,721 4,091 
Balance at end of period$3,646 $3,974 
The following table provides a reconciliation of cash, cash equivalents and restricted cash (2) to the amounts reported on our condensed consolidated balance sheets:
At March 31, 2024At December 31, 2023
Cash and cash equivalents$3,608 $3,686 
Restricted cash included in other current assets8 5 
Restricted cash included in other assets30 30 
Cash, cash equivalents and restricted cash$3,646 $3,721 
(1) Includes $360 million (15% of the Repurchase Price) paid in March 2024 related to the ASR transactions. See Note 1. Background and Basis of Presentation.
(2) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 13. Contingencies.

See notes to condensed consolidated financial statements.
9


Altria Group, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Background and Basis of Presentation
When used in these notes, the terms Altria,” “we,” “us” and “our” refer to either (i) Altria Group, Inc. and its consolidated subsidiaries or (ii) Altria Group, Inc. only and not its consolidated subsidiaries, as appropriate in the context.
Background: At March 31, 2024, our wholly owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and is a wholly owned subsidiary of PM USA; UST LLC (“UST”), which through its wholly owned subsidiary U.S. Smokeless Tobacco Company LLC (“USSTC”), is engaged in the manufacture and sale of moist smokeless tobacco products (“MST”) and snus products; Helix Innovations LLC (“Helix”), which operates in the United States and Canada, and Helix Innovations GmbH and its affiliates (“Helix International”), which operate internationally in the rest-of-world, are engaged in the manufacture and sale of oral nicotine pouches; and NJOY, LLC (“NJOY”), which is engaged in the manufacture and sale of e-vapor products. Other wholly owned subsidiaries included Altria Group Distribution Company (“AGDC”), which provides sales and distribution services to our domestic operating companies; and Altria Client Services LLC (“ALCS”), which provides various support services to our companies in areas such as legal, regulatory, research and product development, consumer engagement, finance, human resources and external affairs. Our access to the operating cash flows of our subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by our subsidiaries. At March 31, 2024, our significant subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.
At March 31, 2024, we also owned a 75% economic interest in Horizon Innovations LLC (“Horizon”), a joint venture with JTI (US) Holding, Inc., a subsidiary of Japan Tobacco Inc., which owned the remaining 25% economic interest. Horizon is structured to exist in perpetuity and is responsible for the U.S. marketing and commercialization of heated tobacco stick products owned by either party.
At March 31, 2024, we had investments in Anheuser-Busch InBev SA/NV (“ABI”) and Cronos Group Inc. (“Cronos”). In March 2024, we sold a portion of our investment in ABI (“ABI Transaction”). For further discussion of our investments in equity securities and the ABI Transaction, see Note 5. Investments in Equity Securities.
Share Repurchases: In January 2023, our Board of Directors (“Board of Directors” or “Board”) authorized a $1.0 billion share repurchase program (“January 2023 share repurchase program”), which we completed in December 2023.
In January 2024, our Board of Directors authorized a new $1.0 billion share repurchase program that it increased to $3.4 billion in March 2024 (as increased, “January 2024 share repurchase program”). In connection with the ABI Transaction, we entered into accelerated share repurchase (“ASR”) transactions under two separate agreements with bank counterparties (collectively, “ASR Agreements”) to repurchase an aggregate $2.4 billion (“Repurchase Price”) of our common stock. In March 2024, we paid the Repurchase Price and received 46.5 million shares of our common stock, which represented an aggregate value of approximately 85% or $2,040 million of the Repurchase Price based on the closing price per share of our common stock on the date we entered into the ASR Agreements. Upon final settlement of each of the ASR transactions (for the remaining 15% or $360 million of the Repurchase Price), which we expect to occur by June 30, 2024, we may be entitled to receive additional shares or, under certain circumstances specified in the ASR Agreements, may be required to deliver shares of our common stock or cash, at our option, to the applicable bank counterparty. The total number of shares to be repurchased under the ASR Agreements will be based on volume-weighted average prices of our common stock during the term of the ASR transactions, less a discount and subject to certain adjustments pursuant to the terms of the ASR Agreements. The ASR transactions are accounted for as equity transactions and included in cost of repurchased stock on our condensed consolidated balance sheet when the shares are received. At March 31, 2024, the remaining $360 million was recorded as a reduction in additional paid in capital on our condensed consolidated balance sheet, and we had $1.0 billion remaining under the January 2024 share repurchase program. The timing of share repurchases depends upon marketplace conditions and other factors, and the program remains subject to the discretion of our Board.

10

Our share repurchase activity, which consisted only of shares purchased under the ASR Agreements, was as follows:
(in millions, except per share data)For the Three Months Ended March 31, 2024
Total number of shares repurchased
46.5 
Aggregate cost of shares repurchased (1)
$2,040 
Average price per share of shares repurchased (2)
$43.87 
(1) Subject to final settlement of each of the ASR transactions, which we expect to occur by June 30, 2024, but may occur earlier in certain circumstances. Until final settlement, $360 million (15% of the Repurchase Price) will remain in additional paid in capital on our condensed consolidated statement of stockholders’ equity (deficit).
(2) The final price per share of shares repurchased under each ASR Agreement will be determined at the end of the applicable purchase period, which is scheduled to occur by June 30, 2024, but may occur earlier in certain circumstances.
For the three months ended March 31, 2023, there were no share repurchases.
Basis of Presentation: Our interim condensed consolidated financial statements are unaudited. Our management believes that all adjustments necessary for a fair statement of the interim results presented have been reflected in our interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.
These statements should be read in conjunction with our audited consolidated financial statements and related notes, which appear in our Annual Report on Form 10-K for the year ended December 31, 2023.
Certain immaterial prior year amounts have been reclassified to conform with the current year’s presentation.
On January 1, 2024, we adopted Accounting Standards Update (“ASU”) 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU No. 2022-03”). This guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance also specifies required disclosures for equity securities subject to contractual sale restrictions. We applied ASU No. 2022-03 for the fair value disclosure of our investment in ABI. For further discussion, see Note 5. Investments in Equity Securities.
For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 14. New Accounting Guidance Not Yet Adopted.
Note 2. Acquisition of NJOY
On June 1, 2023, we acquired NJOY Holdings (“NJOY Transaction”), which provided us with full global ownership of NJOY’s e-vapor product portfolio, including NJOY ACE, currently the only pod-based e-vapor product with market authorizations from the U.S. Food and Drug Administration (“FDA”). The total consideration for the NJOY Transaction of approximately $2.9 billion consisted of approximately $2.75 billion in cash payments (net of cash acquired) plus the fair value of up to $500 million in additional cash payments that are contingent on receipt of FDA authorizations with respect to certain NJOY products. The fair value of these contingent payments at March 31, 2024, December 31, 2023 and on the acquisition date was approximately $130 million, which is included in the total consideration.
We accounted for this acquisition as a business combination. The fair value estimates of the assets acquired and liabilities assumed are preliminary and subject to adjustments during the measurement period (up to one year following the acquisition date). The primary area of accounting for the NJOY Transaction that is not yet finalized is the assessment of contingent liabilities, which could impact the fair value of certain intangible assets acquired and residual goodwill, including any related tax impact.
11

The amounts in the table below represent the preliminary estimates for purchase price allocation to assets acquired and liabilities assumed in the NJOY Transaction, including measurement period adjustments made for the three months ended March 31, 2024. We recorded no measurement period adjustments in 2023. The preliminary purchase price allocation will be finalized by the end of the measurement period.
(in millions)Preliminary Purchase Price Allocation Measurement period adjustments recognized at March 31, 2024Updated Preliminary Purchase Price Allocation
Cash and cash equivalents$22 $ $22 
Receivables7  7 
Inventories19  19 
Other assets7  7 
Property, plant and equipment16  16 
Other intangible assets:
Developed technology (amortizable)1,000  1,000 
Trademarks (amortizable)230 (40)190 
Supplier agreements (amortizable)
180 (180) 
Accounts payable(7) (7)
Accrued liabilities(20) (20)
Deferred income taxes(167)66 (101)
   Total identifiable net assets1,287 (154)1,133 
   Total consideration 2,901  2,901 
Goodwill
$1,614 $154 $1,768 
The excess of the total consideration over the identifiable net assets acquired in the NJOY Transaction primarily reflects the value of future growth opportunities in the e-vapor category. None of the goodwill or other intangible assets is deductible for tax purposes.
The significant assumptions used in determining the preliminary fair values of the identifiable intangible assets included volume growth rates, operating margins, the assessment of acquired technology life cycles, discount rates, as well as other factors. We determined the preliminary fair values of the identifiable intangible assets using an income approach. The fair value measurements were primarily based on significant inputs that are not observable in the market, such as discounted cash flow analyses, and thus are classified in Level 3 of the fair value hierarchy. We amortize the intangible assets over a weighted-average period of approximately 18 years. Following the measurement period adjustments made in the first quarter of 2024, we estimate our total annual pre-tax amortization expense for all of our definite-lived intangible assets, which includes the impact of the NJOY Transaction, to be approximately $150 million for each of the next five years, assuming no additional transactions occur that require the amortization of intangible assets and no impacts of any additional measurement period adjustments related to the NJOY Transaction.
In determining the estimated fair value of contingent payments, we made certain judgments, estimates and assumptions, the most significant of which was the likelihood of certain potential regulatory outcomes. Contingent payments are classified in Level 3 of the fair value hierarchy.
Note 3. Revenues from Contracts with Customers
We disaggregate net revenues based on product type. For further discussion, see Note 10. Segment Reporting.
In 2023, substantially all cash discounts, offered in contracts with our customers for prompt payment, were based on a flat rate per unit based on agreed-upon payment terms. Beginning in the first quarter of 2024 for PM USA and USSTC, cash discounts in contracts with our customers were based on a percentage of the list price based on agreed-upon payment terms. We record receivables net of the cash discounts on our condensed consolidated balance sheets.
We record payments received by our businesses in advance of product shipment as deferred revenue. These payments are included in other accrued liabilities on our condensed consolidated balance sheets until control of such products is obtained by the customer. Deferred revenue from contracts with customers was $234 million and $258 million at March 31, 2024 and December 31, 2023, respectively. When cash is received in advance of product shipment, our companies satisfy their performance obligations within three days of receiving payment. At March 31, 2024 and December 31, 2023, there were no
12

differences between amounts recorded as deferred revenue from contracts with customers and amounts subsequently recognized as revenue.
Receivables were $77 million and $71 million at March 31, 2024 and December 31, 2023, respectively. At March 31, 2024 and December 31, 2023, there were no expected differences between amounts recorded and subsequently received, and we did not record an allowance for credit losses against these receivables.
We record an allowance for returned goods, which is included in other accrued liabilities on our condensed consolidated balance sheets. It is USSTC’s policy to accept authorized sales returns from its customers for products that have passed the freshness date printed on product packaging due to the limited shelf life of USSTC’s MST and snus products. We record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. We reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on our condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, we do not record an asset for USSTC’s right to recover goods from customers upon return.
Sales incentives include variable payments related to goods sold by our businesses. We include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers. The sales incentives that require significant estimates and judgments are as follows:
Price promotion payments- We make price promotion payments, substantially all of which are made to our retail partners to incent the promotion of certain product offerings in select geographic areas.
Wholesale and retail participation payments- We make payments to our wholesale and retail partners to incent merchandising and sharing of sales data in accordance with our trade agreements.
These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates. Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions. Differences between actual and estimated payments are reflected in the period such information becomes available. These differences, if any, have not had a material impact on our condensed consolidated financial statements.
Note 4. Supplier Financing
We facilitate a voluntary supplier financing program through a third-party intermediary under which participating suppliers may elect to sell receivables due from us to participating third-party financial institutions at the sole discretion of both the suppliers and the financial institutions (“Program”). Our responsibility is limited to making payment on the terms originally negotiated with our supplier, regardless of whether our supplier sells its receivable to a financial institution. We pay the third-party intermediary a nominal fee to administer the Program. Under the terms of the agreement with our third-party intermediary, ALCS has a direct obligation to pay the participating financial institutions or the participating suppliers when payment obligations are due, unless such obligations are satisfied by the applicable ALCS affiliate. Additionally, Altria guarantees the obligations of ALCS to those parties. We do not enter into agreements with any of the participating financial institutions in connection with the Program. The range of payment terms we negotiate with our suppliers, up to 120 days, is consistent, irrespective of whether a supplier participates in the Program.
We have no economic interest in a supplier’s sale of a receivable. Once a qualifying supplier elects to participate in the Program and reaches an agreement with a participating third-party financial institution, the qualifying supplier elects which individual invoices they sell to the financial institution.
All outstanding balances under the Program are recorded in accounts payable on our condensed consolidated balance sheets, and the associated payments are included in operating activities within our condensed consolidated statements of cash flows.
At March 31, 2024 and December 31, 2023, confirmed outstanding obligations under the Program were $120 million and $119 million, respectively.
Note 5. Investments in Equity Securities
The carrying amount of our investments consisted of the following:
(in millions)March 31, 2024December 31, 2023
ABI$8,070 $9,676 
Cronos326 335 
Total
$8,396 $10,011 
13

(Income) losses from our current and former investments in equity securities consisted of the following:
For the Three Months Ended March 31,
(in millions)20242023
ABI (1)
$(313)
(2)
$(205)
Cronos (1)
18 35 
(Income) losses from investments under equity method of accounting(295)(170)
JUUL  
 
250 
(3)
(Income) losses from investments in equity securities$(295)$80 
(1) Includes our share of amounts recorded by our investees and additional adjustments, if required, related to (i) the conversion from international financial reporting standards to United States generally accepted accounting principles (“GAAP”) and (ii) adjustments to our investments required under the equity method of accounting.
(2) Includes $165 million of the total pre-tax gain on the ABI Transaction discussed below.
(3) Represents loss as a result of the disposition of our JUUL equity securities discussed below.
Investment in ABI
Prior to March 14, 2024, we had an approximate 10% ownership interest in ABI, consisting of approximately 185 million restricted shares of ABI (“Restricted Shares”) and approximately 12 million ordinary shares of ABI. On March 14, 2024, we converted 60 million shares of our Restricted Shares to ordinary shares of ABI. Our Restricted Shares:
are unlisted and not admitted to trading on any stock exchange;
are convertible by us into ordinary shares of ABI on a one-for-one basis;
rank equally with ordinary shares of ABI with regards to dividends and voting rights; and
have director nomination rights with respect to ABI.
In the ABI Transaction:
On March 14, 2024, we entered into an underwriting agreement in connection with a global secondary offering that closed on March 19, 2024, in which we sold 35 million ordinary shares of ABI for gross proceeds of approximately $2.2 billion (“Secondary Offering”). In connection with the Secondary Offering, we (i) agreed to a 180-day lockup with the lead underwriter with respect to our remaining approximately 159 million ABI shares (ending September 10, 2024) and (ii) granted the underwriters an option to purchase up to an additional 5.25 million ordinary shares of ABI, exercisable within 30 days following the date of the underwriting agreement, which the underwriters did not exercise prior to expiration.
On March 13, 2024, we entered into a share repurchase agreement with ABI, conditioned upon the closing of the Secondary Offering and certain other customary conditions, to sell $200 million of our ABI ordinary shares to ABI in a private transaction. We completed the sale of approximately 3.3 million ordinary shares to ABI on March 19, 2024.
At March 31, 2024, we had an approximate 8.1% ownership interest in ABI, consisting of approximately 125 million Restricted Shares and approximately 34 million ordinary shares of ABI. As a result of the ABI Transaction, in the first quarter of 2024, we received pre-tax cash proceeds totaling approximately $2.4 billion and incurred transaction costs of approximately $62 million. In conjunction with the ABI Transaction, we entered into the ASR Agreements. For further discussion of the ASR Agreements, see Note 1. Background and Basis of Presentation.
14

As a result of the ABI Transaction, we recorded the following pre-tax amounts in our condensed consolidated statement of earnings:
(in millions)For the Three Months Ended March 31, 2024
Gain on partial sale of our investment$165 
Transaction costs(62)
Total pre-tax gain on ABI Transaction$103 
The pre-tax gain on the partial sale of our investment was recorded in (income) losses from investments in equity securities and includes a $408 million gain representing the excess of the selling price of the ABI shares sold over the carrying value of those shares, partially offset by a $243 million reclassification of the proportionate share of our pre-tax accumulated other comprehensive losses directly attributable to ABI and our designated net investment hedges related to our investment in ABI (see Note 6. Financial Instruments and Note 9. Other Comprehensive Earnings/Losses).
The pre-tax transaction costs were approximately $62 million ($59 million in marketing, administration and research costs and $3 million in interest and other debt expense, net), substantially all of which were underwriter fees.
In addition, in conjunction with the ABI Transaction, we recorded an income tax benefit from the partial release of a valuation allowance of approximately $94 million in provision for income taxes in our condensed consolidated statement of earnings for the three months ended March 31, 2024. For further discussion, see Note 12. Income Taxes.
We expect to maintain two seats on ABI’s board of directors through ABI’s 2025 annual general meeting. Following that meeting, as a result of our reduced ownership interest in ABI following the ABI Transaction, we expect to have one seat on ABI’s board of directors, in accordance with our rights as a holder of Restricted Shares. We will continue to account for our investment in ABI under the equity method of accounting because we have active representation on ABI’s board of directors and certain ABI board committees. Through this representation, we have the ability to exercise significant influence over the operating and financial policies of ABI and participate in ABI’s policy making processes.
We report our share of ABI’s results using a one-quarter lag, because ABI’s results are not available in time for us to record them in the concurrent period.
The fair value of our investment in ABI was based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares and was classified in Level 2 of the fair value hierarchy. We can convert our Restricted Shares to ordinary shares at our discretion after the expiration of the 180-day lockup period. The fair value of each Restricted Share is based on the value of an ordinary share.
The fair value of our equity investment in ABI at March 31, 2024 and December 31, 2023 was $9.7 billion and $12.7 billion, respectively, which exceeded its carrying value of $8.1 billion and $9.7 billion, respectively, by approximately 20% and 32%, respectively.
Investment in Cronos
At March 31, 2024, we had a 41.0% ownership interest in Cronos, consisting of approximately 157 million shares, which we account for under the equity method of accounting. We report our share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for us to record them in the concurrent period.
The fair value of our investment in Cronos was based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. At March 31, 2024, the fair value of our investment in Cronos exceeded its carrying value by approximately $85 million or approximately 26%. At December 31, 2023, the fair value of our investment in Cronos was less than its carrying value by $8 million or approximately 2%.
Former Investment in JUUL Labs, Inc. (“JUUL”)
In March 2023, we entered into a stock transfer agreement with JUUL (“Stock Transfer Agreement”) under which we transferred to JUUL all of our beneficially owned JUUL equity securities and, in exchange, received a non-exclusive, irrevocable global license to certain of JUUL’s heated tobacco intellectual property. In addition, all other agreements between us and JUUL were terminated or we were removed as parties thereto, other than certain litigation-related agreements and a license agreement relating to our non-trademark licensable intellectual property rights in the e-vapor field, which remain in force solely with respect to our e-vapor intellectual property as of or prior to March 3, 2023. As a result of the Stock Transfer Agreement, for the three months ended March 31, 2023, we recorded a non-cash, pre-tax loss of $250 million on the disposition of our JUUL equity securities in (income) losses from investments in equity securities in our condensed consolidated statement of earnings.
15

Note 6. Financial Instruments
We enter into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. We use various types of derivative financial instruments, including forward contracts, options and swaps. We do not enter into or hold derivative financial instruments for trading or speculative purposes.
Our investment in ABI, whose functional currency is the Euro, exposes us to foreign currency exchange risk on the carrying value of our investment. To manage this risk, we may designate certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, “foreign currency contracts”), and Euro denominated unsecured long-term notes (“foreign currency denominated debt”) as net investment hedges of our investment in ABI.
At March 31, 2024 and December 31, 2023, we had no outstanding foreign currency contracts. When we have foreign currency contracts in effect, counterparties are domestic and international financial institutions. Under these contracts, we are exposed to potential losses in the event of non-performance by these counterparties. We manage our credit risk by entering into transactions with counterparties that have investment grade credit ratings, limiting the amount of exposure we have with each counterparty and monitoring the financial condition of each counterparty. The counterparty agreements contain provisions that require us to maintain an investment grade credit rating. In the event our credit rating falls below investment grade, counterparties to our foreign currency contracts can require us to post collateral.
The aggregate carrying value and fair value of our total long-term debt were as follows:
(in millions)March 31, 2024December 31, 2023
Carrying value$25,042 $26,233 
Fair value23,130 24,373 
Foreign currency denominated debt included in long-term debt:
Carrying value3,229 3,303 
Fair value3,081 3,125 
Our estimate of the fair value of our total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy.
Net Investment Hedging
We recognize changes in the carrying value of the foreign currency denominated debt due to changes in the Euro to U.S. dollar exchange rate in accumulated other comprehensive losses related to ABI.
We recognized pre-tax (gains) losses of our net investment hedges of $(75) million and $48 million for the three months ended March 31, 2024 and 2023, respectively, in accumulated other comprehensive losses.
In addition, as a result of the ABI Transaction, for the three months ended March 31, 2024, we reclassified $42 million of pre-tax gains from our designated net investments hedges included in accumulated other comprehensive losses to (income) losses from investments in equity securities in our condensed consolidated statement of earnings. For further discussion of the ABI Transaction and reclassification of accumulated other comprehensive losses, see Note 5. Investments in Equity Securities and Note 9. Other Comprehensive Earnings/Losses.
Note 7. Benefit Plans
Components of Net Periodic Benefit Cost (Income)
Net periodic benefit cost (income) consisted of the following:
PensionPostretirement
For the Three Months Ended March 31,
 (in millions)2024202320242023
Service cost$9 $9 $4 $4 
Interest cost80 83 16 17 
Expected return on plan assets
(116)(121)(1)(2)
Amortization:
Net loss (gain)7 1 (1) 
Prior service cost (credit)
1 1 (10)(10)
Net periodic benefit cost (income)$(19)$(27)$8 $9 
16

Employer Contributions
We make contributions to our pension plans to the extent that the contributions are tax deductible and pay benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service regulations. We made employer contributions of $4 million to our pension plans and did not make any contributions to our postretirement plans during the three months ended March 31, 2024. Currently, we anticipate making additional employer contributions of up to approximately $25 million to our pension plans and contributions of up to approximately $30 million to our postretirement plans in 2024. However, the foregoing estimates of 2024 contributions to our pension and postretirement plans are subject to change as a result of changes in tax and other benefit laws, changes in interest rates and asset performance significantly above or below the assumed long-term rate of return for each respective plan.
Note 8. Earnings per Share
We calculated basic and diluted earnings per share (“EPS”) using the following:
For the Three Months Ended March 31,
(in millions)20242023
Net earnings$2,129 $1,787 
Less: Distributed and undistributed earnings attributable to share-based awards(5)(3)
Earnings for basic and diluted EPS$2,124 $1,784 
Weighted-average shares for basic and diluted EPS1,758 1,786 
Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and, therefore, are included in our EPS calculation pursuant to the two-class method.
Note 9. Other Comprehensive Earnings/Losses
Changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria were as follows:
 For the Three Months Ended March 31, 2024
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other
Accumulated
Other
Comprehensive
Losses
Balances, December 31, 2023$(1,493)$(1,195)$15 $(2,673)
Other comprehensive earnings (losses) before reclassifications
 254 6 260 
Deferred income taxes (55) (55)
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
 199 6 205 
Amounts reclassified to net earnings(2)255  253 
Deferred income taxes1 (52) (51)
Amounts reclassified to net earnings, net of deferred income taxes(1)203  202 
Other comprehensive earnings (losses), net of deferred income taxes(1)402 
(1)
6 407 
Balances, March 31, 2024$(1,494)$(793)$21 $(2,266)

17

For the Three Months Ended March 31, 2023
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other
Accumulated
Other
Comprehensive
Losses
Balances, December 31, 2022$(1,436)$(1,369)$34 $(2,771)
Other comprehensive earnings (losses) before reclassifications
 (18)10 (8)
Deferred income taxes 5  5 
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
 (13)10 (3)
Amounts reclassified to net earnings(8)1  (7)
Deferred income taxes2   2 
Amounts reclassified to net earnings, net of deferred income taxes(6)1  (5)
Other comprehensive earnings (losses), net of deferred income taxes(6)(12)
(1)
10 (8)
Balances, March 31, 2023$(1,442)$(1,381)$44 $(2,779)
(1) Primarily reflects our share of ABI’s currency translation adjustments and the impact of our designated net investment hedges related to our investment in ABI. For further discussion of designated net investment hedges, see Note 6. Financial Instruments.
Pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings were as follows:
For the Three Months Ended March 31,
(in millions)20242023
Benefit Plans: (1)
Net loss$7 $1 
Prior service cost/credit(9)(9)
(2)(8)
ABI (2)
255 1 
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings$253 $(7)
(1) Amounts are included in net periodic benefit income, excluding service cost. For further details, see Note 7. Benefit Plans.
(2) Amounts are included in (income) losses from investments in equity securities. For the three months ended March 31, 2024, as a result of the ABI Transaction, we reclassified $243 million from our accumulated other comprehensive losses of which $285 million is directly attributable to ABI, partially offset by $42 million from our designated net investment hedges related to our investment in ABI. For further information, see Note 5. Investments in Equity Securities and Note 6. Financial Instruments.
Note 10. Segment Reporting
At March 31, 2024, our reportable segments were (i) smokeable products, consisting of combustible cigarettes and machine-made large cigars; and (ii) oral tobacco products, consisting of MST, snus and oral nicotine pouches.
Our all other category included (i) NJOY (beginning June 1, 2023); (ii) Horizon; (iii) Helix International; and (iv) other business activities, substantially all of which consists of research and development (“R&D”) expense related to certain new product platforms and technologies.
Our chief operating decision maker (“CODM”) reviews operating companies income (loss) (“OCI”) to evaluate the performance of, and allocate resources to, our segments. OCI for our segments is defined as operating income before general corporate expenses and amortization of intangibles. Interest and other debt expense, net, along with net periodic benefit income, excluding service cost, and provision for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by our CODM.
18

Segment data were as follows:
For the Three Months Ended March 31,
(in millions)20242023
Net revenues:
Smokeable products$4,906 $5,090 
Oral tobacco products651 628 
All other19 1 
Net revenues$5,576 $5,719 
Earnings before income taxes:
OCI:
Smokeable products$2,439 $2,503 
Oral tobacco products435 416 
All other(61)(9)
Amortization of intangibles(27)(18)
General corporate expenses(112)(135)
Operating income2,674 2,757 
Interest and other debt expense, net254 229 
Net periodic benefit income, excluding service cost(24)(31)
(Income) losses from investments in equity securities(295)80 
Earnings before income taxes$2,739 $2,479 
The comparability of OCI for our reportable segments was affected by the following:
Tobacco and Health and Certain Other Litigation Items: We recorded pre-tax charges related to tobacco and health and certain other litigation items as follows:
For the Three Months Ended March 31,
(in millions)20242023
Smokeable products segment$18 $12 
General corporate expenses6 98 
Interest and other debt expense, net 1 
Total$24 $111 
We recorded the amounts shown in the table above for the smokeable products segment and general corporate expenses in marketing, administration and research costs in our condensed consolidated statements of earnings. For further discussion, see Note 13. Contingencies.
Other Business Activities: Our R&D investments have evolved and shifted from our traditional tobacco businesses to new product platforms and technologies. Beginning January 1, 2024, our R&D expense is aligned with how our CODM now evaluates performance results and allocates resources for segment reporting. For the three months ended March 31, 2024, using this approach, we recorded substantially all of our pre-tax R&D expense of $51 million in our all other category, which now includes other business activities related to R&D expense for certain new product platforms and technologies. For the three months ended March 31, 2023, the majority of our pre-tax R&D expense of $43 million was recorded in our smokeable products segment.
Note 11. Debt
Short-term Borrowings and Borrowing Arrangements
At March 31, 2024 and December 31, 2023, we had no short-term borrowings.
We have a $3.0 billion senior unsecured 5-year revolving credit agreement (“Credit Agreement”) that expires on October 24, 2028 and includes an option, subject to certain conditions, for us to extend the term of our Credit Agreement for two additional one-year periods. We intend to use any borrowings under our Credit Agreement for general corporate purposes.
At March 31, 2024, we had availability under our Credit Agreement for borrowings of up to an aggregate principal amount of $3.0 billion.
19

Pricing for interest and fees under our Credit Agreement may be modified in the event of a change in the rating of our long-term senior unsecured debt. We expect interest rates on borrowings under our Credit Agreement to be based on the Term Secured Overnight Financing Rate plus a percentage based on the higher of the ratings of our long-term senior unsecured debt from Moody’s Investors Service, Inc. and Standard & Poor’s Financial Services LLC. The applicable percentage for borrowings under our Credit Agreement at March 31, 2024 was 1.0% based on our long-term senior unsecured debt ratings on that date. Our Credit Agreement does not include any other rating triggers or any provisions that could require the posting of collateral.
Our Credit Agreement includes various covenants, one of which requires us to maintain a ratio of Consolidated EBITDA (earnings before interest, taxes, depreciation and amortization) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis. At March 31, 2024, we were in compliance with our covenants in our Credit Agreement. The terms “Consolidated EBITDA” and “Consolidated Interest Expense,” each as defined in our Credit Agreement, include certain adjustments.
PM USA guarantees any borrowings under our Credit Agreement and any amounts outstanding under our commercial paper program.
Long-term Debt
The aggregate carrying value of our total long-term debt at March 31, 2024 and December 31, 2023 was $25.0 billion and $26.2 billion, respectively.
In January and February 2024, we repaid in full at maturity our 4.000% and 3.800% senior unsecured notes, respectively, in the aggregate principal amount of $776 million and $345 million, respectively.
At March 31, 2024 and December 31, 2023, accrued interest on long-term debt of $248 million and $410 million, respectively, was included in other accrued liabilities on our condensed consolidated balance sheets.
For a discussion of the fair value of our long-term debt and the designation of our Euro denominated senior unsecured notes as a net investment hedge of our investment in ABI, see Note 6. Financial Instruments.
Note 12. Income Taxes
Earnings before income taxes, provision for income taxes and income tax rates consisted of the following:
For the Three Months Ended March 31,
(in millions)20242023
Earnings before income taxes$2,739$2,479
Provision for income taxes610692
Income tax rate22.3 %27.9 %
Our income tax rate for the three months ended March 31, 2024 differs from the U.S. federal statutory rate of 21%, due primarily to state tax expense, partially offset by an income tax benefit from the partial release of a valuation allowance recorded against a deferred tax asset associated with our JUUL-related losses. The valuation allowance release was due to our capital gain on the ABI Transaction.
Our income tax rate for the three months ended March 31, 2023 differs from the U.S. federal statutory rate of 21%, due primarily to state tax expense and a valuation allowance recorded against a deferred tax asset related to the disposition of our former investment in JUUL.
The following chart provides a reconciliation of the beginning and ending valuation allowances for the three months ended March 31, 2024:
(in millions)
Balance at beginning of year$2,256 
Additions to valuation allowance charged to income tax expense7 
Releases of valuation allowance credited to income tax benefit(94)
Foreign currency translation(1)
Reductions to valuation allowance due to NJOY Transaction (no impact to earnings)
(4)
Balance at end of period$2,164 
We determine deferred tax assets and liabilities based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a
20

valuation allowance when it is more likely than not that some portion or all of a deferred tax asset will not be realized. We determine the realizability of deferred tax assets based on the weight of all available positive and negative evidence. In reaching this determination, we consider the character of the assets and the possible sources of taxable income of the appropriate character within the carryback and carryforward periods available under the tax law. There is a potential that sufficient positive evidence may be available in future periods to cause us to further reduce or eliminate the valuation allowance on certain deferred tax assets. That change to the valuation allowance would result in the recognition of previously unrecognized deferred tax assets and a decrease in income tax expense in the period the release is recorded.
The changes in the valuation allowances for the three months ended March 31, 2024 were due primarily to the ABI Transaction. The cumulative valuation allowance at March 31, 2024 was primarily attributable to deferred tax assets recorded in connection with the unrealized capital losses related to our former investment in JUUL and our investment in Cronos. As we continue to evaluate all sources of potential income that may become available to utilize these losses, our valuation allowance position may change. For further discussion of our ABI Transaction, see Note 5. Investments in Equity Securities.
Note 13. Contingencies
Legal proceedings covering a wide range of matters are pending or threatened in various United States and foreign jurisdictions against Altria and certain of our subsidiaries, including PM USA and NJOY, as well as our indemnitees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, income tax liability, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), claims for contribution and claims of competitors, shareholders or distributors. Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.
Litigation is subject to uncertainty, and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrates that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, we may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, under certain circumstances, we may have to pay more than our proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, we also may be required to pay interest and attorneys’ fees.
Although PM USA historically has been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all. However, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases, and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. States, including Florida, also may seek to repeal or alter bond cap statutes through legislation. Although we cannot predict the outcome of such challenges, it is possible that our consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.
We record provisions in our condensed consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 13. Contingencies: (i) management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii) accordingly, management has not provided any amounts in our condensed consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred.
We have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain. It is possible that our consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. We believe, and have been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. We have defended, and will continue to defend, vigorously against litigation challenges. However, we may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.
21

Judgments Paid and Provisions for Tobacco and Health (Including Engle Progeny Litigation) and Certain Other Litigation Items: The changes in our accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:
For the Three Months Ended March 31,
(in millions)20242023
Accrued liability for tobacco and health and certain other litigation items at beginning of period$346 $71 
Pre-tax charges for:
Tobacco and health and certain other litigation (1)
18 

12 
Shareholder derivative lawsuits (2)
 98 
JUUL-related settlements (3)
6  
Related interest costs 1 
Payments(6)

(11)
Accrued liability for tobacco and health and certain other litigation items at end of period$364 $171 
(1) Includes judgments, settlements and fee disputes associated with tobacco and health and certain other litigation.
(2) See Shareholder Class Action and Shareholder Derivative Lawsuits - Federal and State Shareholder Derivative Lawsuits below for a discussion of the settlement of the federal and state shareholder derivative lawsuits.
(3) Includes the settlement of certain e-vapor product litigation relating to JUUL e-vapor products and the e-vapor product litigation brought by the attorneys general of Hawaii, Minnesota and Alaska. See E-vapor Product Litigation below for a discussion of these settlements.
The accrued liability for tobacco and health and certain other litigation items, including related interest costs, was included in accrued liabilities and other liabilities on our condensed consolidated balance sheets. Pre-tax charges for tobacco and health and certain other litigation were included in marketing, administration and research costs in our condensed consolidated statements of earnings. Pre-tax charges for related interest costs were included in interest and other debt expense, net in our condensed consolidated statements of earnings.
After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $1 billion and interest totaling approximately $241 million as of March 31, 2024. These amounts include payments for Engle progeny judgments (and related costs and fees) totaling approximately $440 million and related interest totaling approximately $60 million.
Security for Judgments: To obtain stays of judgments pending appeal, PM USA has posted various forms of security. As of March 31, 2024, PM USA has posted appeal bonds totaling approximately $38 million, which have been collateralized with restricted cash and are included in assets on our condensed consolidated balance sheets.
Overview of Tobacco-Related Litigation
Types and Number of U.S. Cases: Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust, patent infringement and unfair trade practices; and (iv) other tobacco-related litigation described below. Plaintiffs’ theories of recovery and the defenses raised in tobacco-related litigation are discussed below.
22

The table below lists the number of certain tobacco-related cases pending in the United States against us as of:
April 22, 2024April 24, 2023April 25, 2022
Individual Smoking and Health Cases (1)
174167163
Health Care Cost Recovery Actions (2)
111
E-vapor Cases (3)
5,1775,2703,744
Other Tobacco-Related Cases (4)
333
(1) Includes as of April 22, 2024, 20 cases filed in Illinois, 14 cases filed in New Mexico, 63 cases filed in Massachusetts and 41 non-Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle class (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Progeny Cases). Also does not include 1,113 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (Broin). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages but prohibited them from seeking punitive damages. Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.
(2) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below.
(3) Includes as of April 22, 2024, 57 class action lawsuits, 3,614 individual lawsuits and 1,506 “third party” lawsuits relating to the Multidistrict Litigation discussed under E-vapor Product Litigation below. The 57 class action lawsuits include 32 cases in the Northern District of California involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons. In May 2023, we reached agreement on terms to resolve the majority of the Multidistrict Litigation lawsuits. Also includes three patent infringement lawsuits filed against us and certain of our affiliates. For further discussion of the pending Multidistrict Litigation settlement and patent infringement litigation, see E-vapor Product Litigation below.
(4) Includes as of April 22, 2024, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.
International Tobacco-Related Cases: As of April 22, 2024, (i) Altria is named as a defendant in three e-vapor class action lawsuits in Canada; (ii) PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant; and (iii) PM USA and Altria are named as defendants in seven smoking and health class actions filed in various Canadian provinces. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement (defined below) between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.
Tobacco-Related Cases Set for Trial: As of April 22, 2024, one Engle progeny case, two individual smoking and health cases and no e-vapor cases are set for trial through June 30, 2024. Trial dates are subject to change.
Trial Results: Since January 1999, excluding the Engle progeny cases (separately discussed below), verdicts have been returned in 82 tobacco-related cases in which PM USA was a defendant. Verdicts in favor of PM USA and other defendants were returned in 51 of the 82 cases. Of the 31 non-Engle progeny cases in which verdicts were returned in favor of plaintiffs, 27 have reached final resolution.
See Smoking and Health Litigation - Engle Progeny Trial Results below for a discussion of verdicts in state and federal Engle progeny cases involving PM USA as of April 22, 2024.
Smoking and Health Litigation
Overview: Plaintiffs’ allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes and claims under the federal and state anti-racketeering statutes. Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act.
Non-Engle Progeny Litigation: Summarized below are the non-Engle progeny smoking and health cases pending or concluded within the last 12 months in which a verdict was returned in favor of plaintiff and against PM USA. Charts listing certain verdicts for plaintiffs in the Engle progeny cases can be found in Smoking and Health Litigation - Engle Progeny Trial Results below.
23

Taylor: In April 2024, a jury in an Oregon state court returned a verdict in favor of plaintiff and against PM USA, awarding less than $1 million in compensatory damages and allocating 51% of the fault to PM USA. The jury found that plaintiff was not entitled to punitive damages.
Roach: In December 2023, a jury in a Hawaii state court returned a verdict in favor of plaintiff and against PM USA, awarding less than $1 million in compensatory damages and allocating 39% of the fault to PM USA. The jury found that plaintiff was not entitled to punitive damages. Following the verdict, the parties agreed to submit a stipulation of dismissal with prejudice to the court. Pursuant to the agreement, PM USA was not required to pay the damages awarded by the jury, the parties agreed to bear their own costs and the parties agreed not to pursue appeals.
Ricapor-Hall: In August 2023, a jury in a Hawaii state court returned a verdict in favor of plaintiff and against PM USA, awarding $6 million in compensatory damages and $8 million in punitive damages. In October 2023, the court entered judgment against PM USA for $11 million, having reduced the compensatory damages award to $3 million based on the jury’s finding on comparative fault and a set-off against plaintiff’s settlements with other defendants. We filed post-trial motions challenging the verdict, which were denied in March 2024. In April 2024, we filed a notice of appeal and a motion to stay execution pending appeal. Plaintiff has agreed not to oppose the motion to stay and not to attempt to execute on the final judgment until 30 days after all appeals have been exhausted.
Deswert: In May 2023, a jury in a Pennsylvania state court returned a verdict in favor of plaintiff and against PM USA, awarding less than $1 million in compensatory damages and allocating 50% of the fault to PM USA. Despite the comparative fault finding, the compensatory damages award would not have been reduced due to the jury’s finding for plaintiff on the strict liability claim. Plaintiff’s claim for punitive damages was dismissed prior to the trial. In lieu of appealing the trial court’s verdict, PM USA settled plaintiff’s claims in July 2023 for an immaterial amount.
Woodley: In February 2023, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding $5 million in compensatory damages. There was no claim for punitive damages. Following the denial of PM USA’s post-trial motions, PM USA appealed the judgment to the Appeals Court of Massachusetts, and the appeal remains pending.
Fontaine: In September 2022, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $8 million in compensatory damages and $1 billion in punitive damages. In September 2023, the court denied PM USA’s motion for a new trial and partially granted PM USA’s motion for remittitur, reducing the punitive damages award to $56 million. In December 2023, the court entered a final judgment awarding plaintiff $8 million in compensatory damages, $56 million in punitive damages and prejudgment interest. PM USA has noticed an appeal to the Appeals Court of Massachusetts, and the appeal remains pending.
Greene: In September 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiffs and against PM USA, awarding approximately $10 million in compensatory damages. In May 2020, the court ruled on plaintiffs’ remaining claim and trebled the compensatory damages award to approximately $30 million. In February 2021, the trial court awarded plaintiffs attorneys’ fees and costs in the amount of approximately $2.3 million. PM USA appealed the judgment, and, in May 2023, the Massachusetts Supreme Judicial Court affirmed the trial court judgment and orders denying PM USA’s post-trial motions, concluding the case. We recorded a pre-tax charge of approximately $48 million and paid the recorded amount in the second quarter of 2023.
Federal Government’s Lawsuit: See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case.
Engle Progeny Cases: Engle progeny cases are individual smoking and health lawsuits filed by Florida resident plaintiffs against one or more cigarette manufacturer defendants. The lawsuits arose following the Florida Supreme Court’s decertification of the class in Engle, et. al. v. R.J. Reynolds Tobacco Co., et. al., a smoking and health class action lawsuit filed in Florida state court against multiple defendants, including PM USA, in which the jury returned a verdict in favor of the plaintiff class and the trial court assessed punitive damages against the defendants. In July 2006, the Florida Supreme Court mandated that the trial court’s punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate. Plaintiffs in Engle progeny lawsuits are entitled to rely on certain liability findings from the class action lawsuit, substantially reducing each plaintiff’s burden of proof. These liability findings stipulate: (i) that smoking causes various diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants’ cigarettes were defective and unreasonably dangerous; (iv) that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi) that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii) that all defendants sold or supplied cigarettes that were defective; and (viii) that defendants were negligent.
24

Pending Engle Progeny Cases: The deadline for filing Engle progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending. As of April 22, 2024, approximately 288 state court cases were pending against PM USA or Altria asserting individual claims by or on behalf of approximately 357 state court plaintiffs. Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates. Each federal Engle progeny case has been resolved.
Engle Progeny Trial Results: As of April 22, 2024, 145 federal and state Engle progeny cases involving PM USA have resulted in verdicts. Eighty-seven were returned in favor of plaintiffs, five of which have been reversed post-trial or on appeal and remain pending. Fifty-eight verdicts were returned in favor of PM USA, two of which have been reversed post-trial or on appeal and remain pending. In addition, there have been a number of mistrials, only some of which have resulted in new trials as of April 22, 2024.
Post-trial activity in a case can result in final resolution that differs from the initial verdict. In many cases, parties have appealed either compensatory or punitive damages awards or both. Courts also have increased and decreased the amounts of punitive damages juries have awarded, declared mistrials and vacated judgments, in whole or in part, with respect to compensatory and punitive damages awards. Initial verdicts have been reversed in whole or in part on appeal or following retrial. Juries have returned verdicts in favor of or against PM USA awarding no damages. In cases where juries returned verdicts against PM USA awarding no damages, some trial courts have decided to award plaintiff damages notwithstanding the verdict. Cases also have been dismissed with or without prejudice before or after a verdict.
The charts below list the verdicts in and post-trial status of certain Engle progeny cases in which verdicts were returned in favor of plaintiffs. The first chart lists cases that are pending as of April 22, 2024 where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated, and the second chart lists cases that have concluded in the past 12 months. In this Note 13. Contingencies, references to “R.J. Reynolds” are to R.J. Reynolds Tobacco Company. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault. Further, the damages noted reflect adjustments based on post-trial or appellate rulings.
Currently Pending Engle Cases with Verdicts Against PM USA
(rounded to nearest $ million)
PlaintiffVerdict DateDefendant(s)Court
Compensatory Damages(1)
Punitive Damages
(PM USA)
Post-Trial Status
ChaconOctober 2023PM USAMiami-Dade
<$1 million
<$1 million
Appeals to the Third District Court of Appeal pending.
HoffmanJanuary 2023PM USAMiami-Dade
$5 million ($3 million PM USA)
$0
Appeal to the Third District Court of Appeal pending.
LevineSeptember 2022PM USA and R.J. ReynoldsMiami-Dade
$1 million
$0
Third District Court of Appeal affirmed compensatory damages award.
SchertzerApril 2022PM USA and R.J. ReynoldsMiami-Dade$3 million$0PM USA intends to appeal to the Florida Supreme Court.
LippSeptember 2021PM USAMiami-Dade
$15 million
$28 million
Third District Court of Appeal reversed and remanded for a new trial.
McCallMarch 2019PM USABroward
<$1 million (<$1 million PM USA)
<$1 million
Appeal to the Fourth District Court of Appeal pending.
ChadwellSeptember 2018PM USAMiami-Dade
$2 million
$0
Appeal to the Third District Court of Appeal pending.
Kaplan (McLaughlin)
July 2018PM USA and R.J. ReynoldsBroward
$2 million
$0
Appeal to the Fourth District Court of Appeal pending.
Cooper (Blackwood)
September 2015PM USA and R.J. ReynoldsBroward
$5 million
(<$1 million PM USA)
$0
Retrial of punitive damages claim pending.
(1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.
25


Engle Cases Concluded Within Past 12 Months
(rounded to nearest $ million)
PlaintiffVerdict DateDefendant(s)CourtPayment Amount for Damages (if any)
DuignanFebruary 2020PM USA and R.J. ReynoldsPinellas$1 million
FerraiuoloNovember 2023PM USA and R.J. ReynoldsDuval
<$1 million
GarciaMay 2021PM USAMiami-Dade$3 million
HollimanFebruary 2019PM USAMiami-Dade$3 million
Other Smoking and Health Class Actions: Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts. In general, these cases have purported to be brought on behalf of residents of a particular state or states (although a few cases have purported to be nationwide in scope) and have raised addiction claims and, in many cases, claims of physical injury as well.
Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas (1), California (1), Delaware (1), the District of Columbia (2), Florida (2), Illinois (3), Iowa (1), Kansas (1), Louisiana (1), Maryland (1), Michigan (1), Minnesota (1), Nevada (29), New Jersey (6), New York (2), Ohio (1), Oklahoma (1), Oregon (1), Pennsylvania (1), Puerto Rico (1), South Carolina (1), Texas (1) and Wisconsin (1). See Certain Other Tobacco-Related Litigation below for a discussion of “Lights” and “Ultra Lights” class action cases and medical monitoring class action cases pending against PM USA.
As of April 22, 2024, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario. In Saskatchewan, British Columbia (two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants’ cigarettes. In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants’ cigarettes. In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to us) seeking protection under Canada’s Companies’ Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the United States). The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products.
Health Care Cost Recovery Litigation
Overview: In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages. Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.
Although there have been some decisions to the contrary, most judicial decisions in the United States have dismissed all or most health care cost recovery claims against cigarette manufacturers. Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs’ claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions. The U.S. Supreme Court has refused to consider plaintiffs’ appeals from the cases decided by five federal circuit courts of appeal.
In addition to the cases brought in the United States, health care cost recovery actions have been brought against tobacco industry participants, including PM USA and Altria, in Canada (10 cases), and other entities have stated that they are considering